{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:18:56Z","timestamp":1791220736671,"version":"4.1.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,11,26]],"date-time":"2015-11-26T00:00:00Z","timestamp":1448496000000},"content-version":"vor","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1DP2OD008752-01"],"award-info":[{"award-number":["1DP2OD008752-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1038\/jid.2015.252","type":"journal-article","created":{"date-parts":[[2015,7,2]],"date-time":"2015-07-02T13:50:57Z","timestamp":1435845057000},"page":"2873-2876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Dual mTOR Inhibition Is Required to Prevent TGF-\u03b2-Mediated Fibrosis: Implications for Scleroderma"],"prefix":"10.1016","volume":"135","author":[{"given":"Anupam","family":"Mitra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus I.","family":"Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina I.","family":"Marusina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Merleev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smriti","family":"Kundu-Raychaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siba P.","family":"Raychaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanual","family":"Maverakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/jid.2015.252_bb0010","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11926-007-0008-z","article-title":"New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma","volume":"9","author":"Abraham","year":"2007","journal-title":"Curr Rheumatol Rep."},{"key":"10.1038\/jid.2015.252_bb0015","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/1535-7163.MCT-10-1099","article-title":"Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin","volume":"10","author":"Bhagwat","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1038\/jid.2015.252_bb0020","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrrheum.2011.149","article-title":"Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities","volume":"8","author":"Bhattacharyya","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1038\/jid.2015.252_bb0025","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.intimp.2013.08.009","article-title":"1,25-Dihydroxyvitamin D3-3-bromoacetate, a novel vitamin D analog induces immunosuppression through PI3K\/Akt\/mTOR signaling cascade","volume":"17","author":"Datta-Mitra","year":"2013","journal-title":"Int Immunopharmacol"},{"key":"10.1038\/jid.2015.252_bb0030","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1089\/lrb.2008.1006","article-title":"Efficacy of rapamycin in scleroderma: a case study","volume":"6","author":"Fried","year":"2008","journal-title":"Lymphat Res Biol"},{"key":"10.1038\/jid.2015.252_bb0035","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/1523-1747.ep12276895","article-title":"Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma","volume":"92","author":"Gay","year":"1989","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1038\/jid.2015.252_bb0040","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1177\/1087057114545650","article-title":"Detection of PI3K inhibition in human neuroblastoma using multiplex luminex bead immunoassay: a targeted approach for pathway analysis","volume":"19","author":"Lang","year":"2014","journal-title":"J Biomol Screen"},{"key":"10.1038\/jid.2015.252_bb0045","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1089\/ten.tec.2010.0410","article-title":"Multiscale biomimetic topography for the alignment of neonatal and embryonic stem cell-derived heart cells","volume":"17","author":"Luna","year":"2011","journal-title":"Tissue Eng Part C Methods"},{"key":"10.1038\/jid.2015.252_bb0050","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1600-0625.2007.00550.x","article-title":"mTOR as a potential therapeutic target for treatment of keloids and excessive scars","volume":"16","author":"Ong","year":"2007","journal-title":"Exp Dermatol"},{"key":"10.1038\/jid.2015.252_bb0055","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/0019-5154.123499","article-title":"mTOR Signaling Cascade in Psoriatic Disease: Double Kinase mTOR Inhibitor a Novel Therapeutic Target","volume":"59","author":"Raychaudhuri","year":"2014","journal-title":"Indian J Dermatol"},{"key":"10.1038\/jid.2015.252_bb0060","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/jid.2009.318","article-title":"A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity","volume":"130","author":"Sargent","year":"2010","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1038\/jid.2015.252_bb0065","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1002\/art.24986","article-title":"Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study","volume":"60","author":"Su","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1038\/jid.2015.252_bb0070","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jdermsci.2014.02.002","article-title":"Effects of the immunosuppressant rapamycin on the expression of human alpha2(I) collagen and matrix metalloproteinase 1 genes in scleroderma dermal fibroblasts","volume":"74","author":"Tamaki","year":"2014","journal-title":"J Dermatol Sci"},{"key":"10.1038\/jid.2015.252_bb0075","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1002\/art.27498","article-title":"Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis","volume":"62","author":"Yoshizaki","year":"2010","journal-title":"Arthritis Rheum"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X15418755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X15418755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T22:16:24Z","timestamp":1743977784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X15418755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":14,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0022202X15418755"],"URL":"https:\/\/doi.org\/10.1038\/jid.2015.252","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual mTOR Inhibition Is Required to Prevent TGF-\u03b2-Mediated Fibrosis: Implications for Scleroderma","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/jid.2015.252","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Society for Investigative Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}